Atossa Therapeutics, Inc.
ATOSSA THERAPEUTICS, INC. is a clinical-stage biopharmaceutical company developing (Z)-endoxifen, an active metabolite of Tamoxifen, for indications including breast cancer and Duchenne muscular dystrophy.
Business. ATOSSA THERAPEUTICS, INC. (ATOS) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ATOSSA THERAPEUTICS, INC. (ATOS) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
ATOSSA THERAPEUTICS maintains a debt-free capital structure with $31.7 million in cash and equivalents against $7.5 million in total liabilities, resulting in a current ratio of 4.92 and a debt-to-equity ratio of 0.0. The company holds $30.5 million in total equity, supporting a market capitalization of $47.1 million at a price-to-book ratio of 1.54. Despite strong liquidity metrics, the firm generated negative operating cash flow of $9.6 million in Q1 2026, reflecting its pre-revenue status and reliance on capital reserves to fund operations.
Profitability remains negative, with a net income loss of $9.6 million and an operating income loss of $9.9 million in the latest period. Return on equity stands at -31.45% and return on assets at -25.27%, consistent with early-stage biopharma profiles where R&D expenditures exceed any commercial revenue. The company has not yet established an ongoing source of revenue sufficient to cover operating costs, leading to substantial doubt regarding its ability to continue as a going concern without additional capital infusion.
Revenue concentration is non-existent as the company has no commercial product sales. The business model relies entirely on the successful development and eventual commercialization of its lead program, (Z)-endoxifen. Geographic exposure is primarily domestic, with operations and regulatory interactions centered in the United States, though the company notes risks related to international supply chains and geopolitical instability affecting its ability to access capital markets and maintain supplier contracts.
Growth trajectory is defined by clinical development milestones rather than top-line revenue expansion. The company has incurred consistent operating losses, with Q1 2026 net income at -$9.6 million. Historical data indicates a pattern of negative cash flows driven by research and development expenses. The absence of revenue means traditional growth metrics are inapplicable; value creation depends on binary clinical outcomes and potential partnership or licensing deals for its pipeline assets.
Risk factors are elevated, with a medium dilution risk and high liquidity risk flagged in the assessment. Key concerns include the substantial doubt over going-concern status, dependence on external capital to fund operations, and the potential need for equity offerings to sustain clinical trials. The company faces regulatory risks related to FDA approval timelines, clinical trial enrollment, and the success of its (Z)-endoxifen studies. Additionally, the company must maintain compliance with Nasdaq listing requirements, which may be threatened by low share price or market cap levels.
Recent events include the filing of a 10-K highlighting going-concern risks and the potential for future capital raises. The stock printed a new 52-week low of $2.48 on elevated volume in June 2026, signaling market pessimism. Analyst estimates remain positive with a mean price target of $22.00, suggesting a significant disconnect between current market pricing and analyst expectations for future clinical success or partnership value. The company also disclosed a reverse stock split as a subsequent event, aimed at maintaining listing compliance.
- ATOSSA THERAPEUTICS holds $31.7M in cash with no debt, providing a runway but facing substantial doubt over going-concern status due to lack of revenue.
- The company reported a Q1 2026 net loss of $9.6M, with negative ROE of -31.45% and ROA of -25.27%, typical for pre-revenue biopharma.
- Dilution risk is medium, driven by the need for external capital to fund R&D and the existence of warrants and convertible preferred stock.
- The stock hit a 52-week low of $2.48 in June 2026, despite analyst mean price targets of $22.00, indicating high volatility and speculative interest.
- Clinical development of (Z)-endoxifen for breast cancer and DMD is the primary value driver, with success dependent on FDA approval and trial outcomes.
- A reverse stock split was executed to maintain Nasdaq listing compliance, highlighting pressure on share price and market capitalization.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income -$9.9M.
- ▍Operating income -$9.9M
Operating income -$25.7M.
- ▍Operating income -$25.7M
Operating income -$16.5M.
- ▍Operating income -$16.5M
Operating income -$37.1M.
- ▍Operating income -$37.1M
Operating income -$27.6M.
- ▍Operating income -$27.6M
Operating income -$27.6M.
- ▍Operating income -$27.6M
Operating income -$31.4M.
- ▍Operating income -$31.4M
Operating income -$31.4M.
- ▍Operating income -$31.4M
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -4,30 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -38,1M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Filings reference going-concern or substantial-doubt language.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director, President & CEO · Stock Options (right to buy) → Common StockAcquired 950 000 @ $0,60grant · 2026-01-20
- Chief Financial Officer · Stock Option (right to buy) → Common StockAcquired 578 000 @ $1,03grant · 2025-10-14
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- Return On Assetsnet_income / total_assets
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Enterprise Valuemarket_cap - net_cash
- Cash Conversion Ratiooperating_cash_flow / net_income
- ATOSSA THERAPEUTICS, INC. company facts · 2026-07-12
- ATOSSA THERAPEUTICS, INC. 10-Q 2026-05-08 · 2026-07-12
- ATOSSA THERAPEUTICS, INC. 10-K 2026-03-25 · 2026-07-12
- ATOSSA THERAPEUTICS, INC. 10-Q 2025-11-12 · 2026-07-12
- ATOSSA THERAPEUTICS, INC. 10-Q 2025-08-12 · 2026-07-12
- ha_price_52w fired on ATOS · 2026-07-12
- Atossa Therapeutics Inc Market data — analyst estimates · 2026-07-12
- Atossa Therapeutics Inc Market data — ESG · 2026-07-12
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$11M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$4M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
Insider activity
- Director · Common StockOther 10 000 · 2026-05-12
- Director · Common StockOther 10 000 · 2026-05-12
- Director · Common StockOther 10 000 · 2026-05-12
- Director · Common StockOther 10 000 · 2026-05-12
- Director · Common StockOther 10 000 · 2026-05-12
- Director · Common StockOther 10 000 · 2026-05-12
- Director, President & CEO · Common StockOther 65 000 · 2026-03-27
- Chief Financial Officer · Common StockOther 63 000 · 2026-03-26
- Director, President & CEO · Common StockOther 325 203 · 2026-01-20
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -41.9%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.21xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 21.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -32.9%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -32.9%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 66.2%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -37.7%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -44.9%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 50.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -34.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -41.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -88.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -36.3%Derived (calculated)
- Return on assets (FY 2025-12-31): -73.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 5.53xDerived (calculated)
- Capex (annual): USD 23KSEC XBRL filing
- Total liabilities (annual): USD 8.26MSEC XBRL filing
- Cash & equivalents (annual): USD 41.3MSEC XBRL filing
- Total operating expenses (annual): USD 37.14MSEC XBRL filing
- Net income (annual): USD -34.77MSEC XBRL filing
- Pre-tax income (annual): USD -34.77MSEC XBRL filing
- Current assets (annual): USD 45.62MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -4SEC XBRL filing
- Operating income (annual): USD -37.14MSEC XBRL filing